We get our first look at data for NOX66 on Tuesday 12 September in Australia when Noxopharm publishes a poster at the 2017 ESMO Annual Meeting in Madrid. We already know that safety data for patients in Georgia will be good, but my hope is that the poster will also publish preliminary efficacy for the first four patients.
As for the degree of any response, we need to be realistic. It is rare to see tumour shrinkage in any phase I trial, and in the case being reported patients will only have received low-dose Carboplatin (AUC=4) in combination with low-dose NOX66 (400 mg/day). It will be quite an achievement if this regime stops tumour growth, given that growth was out of control in all patients. Stable disease would be a good result.
Any tumour shrinkage would be extraordinary.
Add to My Watchlist
What is My Watchlist?
